ATIM-19. POPULATION PHARMACOKINETIC (PPK) ANALYSIS OF NIVOLUMAB FLAT AND WEIGHT-BASED DOSING REGIMENS AND ASSOCIATIONS WITH SAFETY IN PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM) TREATED IN CHECKMATE 143

BACKGROUND: Nivolumab 3 mg/kg Q2W was well tolerated in rGBM in CheckMate 143 (NCT02017717). It is unknown if nivolumab PK will differ in rGBM vs other tumor types; therefore, a PPK analysis was performed to compare nivolumab PK in patients with rGBM vs those with NSCLC. Additionally, this analysis...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Shen, Jun, Hruska, Matthew, Zwirtes, Ricardo, Potter, Von, Paliwal, Prashni, Roy, Amit, Bello, Akintunde, Suryawanshi, Satyendra, Lim, Michael
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2017
Assuntos:
Abstracts
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692350/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.114
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares